SCHEMBL9044166

SCHEMBL9044166

C[C](c1ccccc1)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 5/20 0.52
CES2 O00748 3/20 0.42
ALDH1A1 P00352 5/20 0.38
TSHR P16473 3/20 0.38
DAO P14920 1/20 0.38
NAPRT Q6XQN6 1/20 0.38
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
MLYCD O95822 1/20 0.37
ESR1 P03372 1/20 0.37
MAPK1 P28482 2/20 0.36
RAB9A P51151 2/20 0.36
TRPA1 O75762 1/20 0.36
GSK3B P49841 1/20 0.36
HIF1A Q16665 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 1/20 0.36
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7698518 0.76 CES1 (0.44) CES1CES2ALDH1A1TSHRDAO
SCHEMBL28449348 0.75 CES1 (0.48) CES1CES2ALDH1A1TSHRDAO
SCHEMBL28830743 0.75 CES1 (0.54) CES1CES2ALDH1A1TSHRDAO
SCHEMBL3281774 0.74 CES2 (0.52) CES1CES2ALDH1A1TSHRDAO
SCHEMBL5255384 0.73 CES2 (0.50) CES1CES2ALDH1A1MAPK1RAB9A
SCHEMBL28271260 0.73 CES1 (0.46) CES1CES2ALDH1A1TSHRDAO
Acetophenone SCHEMBL28740713 0.73 CES1 (0.58) CES1CES2ALDH1A1TSHRDAO
SCHEMBL536996 0.72 CES1 (0.56) CES1CES2ALDH1A1TSHRDAO
SCHEMBL4630453 0.72 CES1 (0.56) CES1CES2ALDH1A1TSHRDAO
SCHEMBL10808879 0.72 CES1 (0.56) CES1CES2ALDH1A1TSHRDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663502-B2 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease LYCERA CORPORATION (US) 2017-05-30 US claimed
US-9663502-B2 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease LYCERA CORPORATION (US) 2017-05-30 US disclosed
US-20160304505-A1 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE MERCK SHARP & DOHME LLC 2016-10-20 US disclosed
WO-2015095788-A1 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed
EP-0695295-A1 3-(HETERO)ARYL CARBOXYLIC ACID DERIVATIVES, METHODS OF PREPARING THEM AND INTERMEDIATES USED IN THEIR PREPARATION BASF AKTIENGESELLSCHAFT (DE) 1996-02-07 EP disclosed
US-5405867-A Milbemycin derivatives with insecticidal and anthelmintic properties; for plants and animals SANKYO COMPANY, LIMITED (JP) 1995-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304505-A1 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE RORA, RORB, RORC CES1 905/4885CES2 2513/4885ALDH1A1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.